EUCTR2013-001194-25-ES进行中（未招募）1 期
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Tadalafil for Duchenne Muscular Dystrophy
illy S.A.0 个研究点目标入组 306 人开始时间: 2013年6月26日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 306
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •? Males with proven DMD
- •? Ages 7-14 years inclusive
- •? Ambulant, defined as baseline 6MWD between 200 and 400 meters inclusive
- •? 6MWD measurements within 20% of each other at a minimum of 2 pre-randomization assessments
- •? Left ventricular ejection fraction (LVEF) ?50%
- •? Receiving corticosteroids for a minimum of 6 months immediately prior to screening, with no significant change in total daily dosage or dosing regimen (except those adjusting for weight changes) for a minimum of 3 months immediately prior to screening and a reasonable expectation that total daily dosage and dosing regimen will not change significantly (except for adjustments for weight) for the duration of the study. Corticosteroid treatment regimen can be daily, intermittent, high-dose weekend, or alternate days, but must be consistent with current clinical care recommendations.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 306
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •? Symptomatic cardiomyopathy or heart failure (New York Heart Association Class III or IV)
- •? Change (initiation, change in type of drug, dose modification, schedule modification, interruption, discontinuation, or reinitiating) in prophylactic treatment for heart failure within 3 months prior to start of study treatment
- •? Cardiac rhythm disorder defined as sinus rhythm with ectopic contractions or conductance disturbances, or any rhythm other than sinus, observed on screening ECG
- •? Use of continuous mechanical ventilator assistance. [Evening use of bi-level positive airway pressure (BPAP) or continuous positive airway pressure (CPAP) therapy is allowed]
- •? Previous treatment with investigational drugs or interventions (including shock training system) within 3 months of the first administration of study medication, or planned use during the study
- •? History of participation in gene or cell-based therapy
- •? History of antisense oligonucleotide (AON) or stop codon read-through therapy
- •? Unable to take orally administered tablets (without chewing, crushing or breaking), as assessed by the investigator
- •? Use of L-arginine supplements within 4 weeks (+/- 1 day) of the first administration of study medication
- •? Use of any pharmacologic treatment, other than corticosteroids, that might have an effect on muscle strength within 3 months prior to the start of study treatment (e.g., growth hormone, anabolic steroids including testosterone). Vitamin D, calcium, and combinations thereof will be allowed.
- •? New or changed treatment with herbal or dietary supplements being taken with an expectation of an effect on muscle strength or function during 1 month prior to first dose of study drug. Patients taking herbal or dietary supplements as defined above with no change in type or dose for 1 month prior to first dose of study drug with no expectation of adding or changing supplements for the 48 week double-blind period may be enrolled.
- •? Surgery that might have an effect on muscle strength or function within 3 months before study entry or planned surgery at any time during the study
- •? Evidence of a lower limb injury that may in the judgment of the investigator affect performance on the 6MWD
- •? Severe behavioral problems, including severe autism or attention deficit disorders, that may in the judgment of the investigator interfere with completion of the 6MWD
- •? Any contraindication to tadalafil (use of any form of organic nitrate, either regularly and/or intermittently, or known serious hypersensitivity to tadalafil)
- •? History of significant renal insufficiency, defined as receiving renal dialysis or having a screening serum cystatin C level ? 2.35 mg/L
- •? Clinical evidence of cirrhosis
- •? Diagnosed with a retinal disorder (for example, hereditary retinal disorders, retinopathy of prematurity)
- •? Have severe hypotension or uncontrolled hypertension as determined by the investigator
- •? Current treatment with potent CYP3A4 inhibitors, such as antiretroviral therapy (protease inhibitor), systemic ketoconazole, or systemic itraconazole, or chronic use of potent CYP3A4 inducers, such as rifampicin
- •? Currently receiving treatment with doxazosin, nitrates, or cancer therapy
- •? Have known allergy to any of the excipients in tadalafil tablets, notably lactose
- •? Current PDE5 inhibitor therapy or treatment within the past 6 months
- •? Other medical condition deemed to place the patient at potential increased risk or reduced adherence to the study protocol
研究者
相似试验
进行中（未招募）
1 期
Myelofibrosis: Phase 3 Study of Navitoclax Plus Ruxolitinib Versus RuxolitinibMedDRA version: 20.0Level: PTClassification code 10028537Term: MyelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MyelofibrosisEUCTR2020-000097-15-SEAbbVie Deutschland GmbH & Co. KG230
进行中（未招募）
1 期
A study of Doxorubicin plus Olaratumab versus Doxorubicin plus Placebo in Patients with Soft Tissue SarcomaAdvanced or Metastatic Soft Tissue SarcomaMedDRA version: 20.0Level: HLTClassification code 10041298Term: Soft tissue sarcomas histology unspecifiedSystem Organ Class: 100000004864EUCTR2015-000134-30-PLEli Lilly and Company460
进行中（未招募）
1 期
Myelofibrosis: Phase 3 Study of Navitoclax Plus Ruxolitinib Versus RuxolitinibMedDRA version: 20.0Level: PTClassification code 10028537Term: MyelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MyelofibrosisEUCTR2020-000097-15-BEAbbVie Deutschland GmbH & Co. KG230
进行中（未招募）
1 期
A study to determinate the safety and efficacy of LY3471851 in Adult Patients with Systemic Lupus ErythematosusMedDRA version: 21.1Level: PTClassification code 10042945Term: Systemic lupus erythematosusSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersSystemic Lupus ErythematosusEUCTR2019-003323-38-DEEli Lilly & Company280
进行中（未招募）
1 期
A study to assess whether different doses of KVD824 are effective in preventing attacks of Hereditary Angiodedema Type I or Type II.Hereditary Angioedema Type I or IIMedDRA version: 21.0Level: LLTClassification code 10080956Term: Hereditary angioedema type ISystem Organ Class: 100000004850MedDRA version: 24.0Level: LLTClassification code 10080960Term: Hereditary angioedema type IISystem Organ Class: 100000004850EUCTR2021-000136-59-BGKalvista Pharmaceuticals Ltd48